AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Autologous cell therapy market surpasses $10.1 billion in 2025, fueled by gene editing and biotech advancements.
ByAinvest
Wednesday, Nov 19, 2025 10:12 am ET1min read
The autologous cell therapy market reached $10.1 billion in 2025, with biotech companies racing to develop therapies for age-related diseases and metabolic disorders. Cell harvesting infrastructure expanded to support next-generation manufacturing, driving momentum across platforms. Publicly traded companies at the intersection of cell engineering, protein delivery, and precision medicine are gaining attention, including Avant Technologies, Sana Biotechnology, Lineage Cell Therapeutics, and CRISPR Therapeutics.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet